The global melanoma cancer diagnostics market is witnessing significant growth due to the increasing incidence of melanoma worldwide. Melanoma, a type of skin cancer, requires early detection and accurate diagnosis for effective treatment. Advancements in diagnostic technologies, such as molecular diagnostics and imaging techniques, have improved the precision and efficiency of melanoma diagnosis. Government initiatives, funding for research, and the growing demand for personalized medicine are also driving the market. The market is poised to expand as healthcare expenditure rises and access to healthcare facilities improves globally.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-melanoma-cancer-diagnostics-market
Data Bridge Market Research analyses that the Melanoma Cancer Diagnostics Market is growing with a CAGR of 7.2% in the forecast period of 2023 to 2030 and is expected to reach USD 7,525.28 million by 2030. The rising prevalence of melanoma cancer worldwide is a significant driver for the growth of the melanoma cancer diagnostics market. The growing awareness about early detection and diagnosis of melanoma has led to an increased demand for effective diagnostic tools and techniques.
Key Findings of the Study
Growing demand for personalized medicine is expected to drive the market's growth rate
The need for targeted therapies and precise diagnostic tools drives the growing demand for personalized medicine in melanoma cancer diagnostics. Advanced diagnostics can identify specific genetic mutations and biomarkers associated with melanoma, enabling personalized treatment approaches tailored to individual patients. These tools provide insights into the molecular characteristics of tumors, helping healthcare professionals make informed treatment decisions and improve patient outcomes. Personalized medicine enhances the effectiveness of melanoma treatments, resulting in better patient outcomes and a higher quality of care.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Nanostring (U.S.), Thermo Fisher Scientific Inc. (U.S.),Quest Diagnostics Incorporated (U.S.),Agilent Technologies, Inc. (U.S.),QIAGEN (Germany), Inivata Ltd (U.K.), F. Hoffman-La Roche Ltd (Switzerland), Abbott (U.S.), AMLo Biosciences Limited (U.K.), Myriad Genetics Inc (U.S.), Castle Biosciences (U.S.), DermTech (U.S.), Michael Diagnostics Ltd (U.K.), Damae Medical (France), Skin Analytics (U.K.),DermLite (U.S.),DermaSensor (U.S.), Skyline Dx (Netherlands), Neracare GmbH (Germany), VERISKIN INC. (U.S.), Illumina Inc (U.S.), bioMerieux SA (Marcy-l'Étoile, France)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The melanoma cancer diagnostics market is segmented on the basis of product type, test type, distribution channel, and end user.
- On the basis of product type, the global melanoma cancer diagnostics market is segmented into instruments, consumables and accessories, and others. In 2023, the instruments segment is expected to dominate the global melanoma cancer diagnostics market with a CAGR of 7.8% in the forecast period of 2023 to 2030 due to the wide adoption of new technologies and easy accessibility for laboratory professionals
In 2023, the instruments segment is expected to dominate the global melanoma cancer diagnostics market
In 2023, the instruments segment is expected to dominate the global melanoma cancer diagnostics market owing to the accurate and efficient diagnosis by enabling the detection of melanoma-specific biomarkers and providing valuable insights into disease progression with a CAGR of 7.8% in the forecast period of 2023 to 2030
- On the basis of test type, the global melanoma cancer diagnostics market is segmented into biomarkers test, imaging test, biopsy, fluorescent in situ hybridization (FISH) tests, comparative genomic hybridization (CGH) tests, immunohistochemical (IHC) tests, and others. In 2023, the imaging test segment is expected to dominate the global melanoma cancer diagnostics market with a CAGR of 8.4% in the forecast period of 2023 to 2030 due to faster diagnostics and easy accessibility for users.
- On the basis of end user, the global melanoma cancer diagnostics market is segmented into into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others. In 2023, the hospitals segment is expected to dominate the global melanoma cancer diagnostics market with a CAGR of 8.5% in the forecast period of 2023 to 2030 due to a rise in patient encouragement for the early detection of melanoma cancer.
- On the basis of distribution channel, the global melanoma cancer diagnostics market is segmented into into direct tender and retail sales. In 2023, the direct tender segment is expected to dominate the global melanoma cancer diagnostics market with a CAGR of 7.8% in the forecast period of 2023 to 2030 due to the rising awareness of the early diagnosis of melanoma cancer.
In 2023, the direct tender segment is expected to dominate the distribution channel segment of the global melanoma cancer diagnostics market
In 2023, the direct tender segment is expected to dominate the global melanoma cancer diagnostics market owing to secure contracts with healthcare providers, government organizations, or research institutions. This channel ensures a direct relationship between manufacturers and end-users, allowing for efficient procurement and supply chain management with a CAGR of 7.8% in the forecast period of 2023 to 2030
Major Players
Data Bridge Market Research recognizes the following companies as the major melanoma cancer diagnostics market players in melanoma cancer diagnostics market are Nanostring (U.S.), Thermo Fisher Scientific Inc. (U.S.),Quest Diagnostics Incorporated (U.S.),Agilent Technologies, Inc. (U.S.),QIAGEN (Germany), Inivata Ltd (U.K.), F. Hoffman-La Roche Ltd (Switzerland), Abbott (U.S.), AMLo Biosciences Limited (U.K.), Myriad Genetics Inc (U.S.), Castle Biosciences (U.S.)
Market Development
- In 2022, Quest Diagnostics Incorporated announced that the company has collaborated with Decode health to get biomarker-based data that can help reduce the time and cost of developing novel diagnostic tests and drug targets for different types of cancer.
- In 2022, Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to the company's growing oncology portfolio. This results in growing liquid biopsy space for the precise tumor test
Regional Analysis
Geographically, the countries covered in the melanoma cancer diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is expected to dominate the region in the melanoma cancer diagnostics market during the forecast period 2023-2030
North America is poised to dominate the global melanoma cancer diagnostics market due to several factors. The region's robust healthcare infrastructure, increasing demand for high-quality healthcare services, and rising awareness about the importance of early cancer detection contribute to market dominance. Additionally, the growing preference for non-invasive testing methods, such as molecular diagnostics and imaging techniques, further drives the market. These factors position North America as a leading market for melanoma cancer diagnostics in the forecast period.
For more detailed information about the melanoma cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/reports/global-melanoma-cancer-diagnostics-market
